Seres Therapeutics (MCRB) Q3 2025 results; investor deck posted

Rhea-AI Filing Summary

FAQ

8-K Event Classification

What did Seres Therapeutics (MCRB) announce in this 8-K?

Which exhibits accompany the MCRB 8-K?

Are the materials considered filed with the SEC?

Where can investors access the presentation?

What period do the results cover for MCRB?

What is the trading symbol and listing for Seres Therapeutics?

Seres Therapeutics (MCRB) furnished an update via Form 8-K announcing financial results for the quarter ended September 30, 2025 and providing operational updates.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Seres Therapeutics (MCRB) furnished an update via Form 8-K announcing financial results for the quarter ended September 30, 2025 and providing operational updates. The company also shared an updated corporate presentation for investors.

The press release is furnished as Exhibit 99.1 and the investor slide deck as Exhibit 99.2. Consistent with Items 2.02 and 7.01, these materials are furnished, not filed, and are not subject to Section 18 liabilities or incorporation by reference except as expressly stated.

3 items: 2.02, 7.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

It announced financial results for the quarter ended September 30, 2025 and provided operational updates.

Exhibit 99.1 is the press release dated November 5, 2025; Exhibit 99.2 is the corporate presentation as of November 2025.

No. Information under Items 2.02 and 7.01, including Exhibits 99.1 and 99.2, is furnished, not filed, and not subject to Section 18 liabilities.

On the company’s website in the Investors and News section at www.serestherapeutics.com.

The quarter ended September 30, 2025.

SERES THERAPEUTICS, INC.

Date: November 5, 2025

/s/ Thomas J. DesRosier

Thomas J. DesRosier

Co-Chief Executive Officer, Co-President,

Executive Vice President, Chief Legal Officer and Secretary

The common stock trades on Nasdaq (Global Select Market) under the symbol MCRB.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 11/05/2025 - 07:05 AM EST

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 5, 2025

SERES THERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware

001-37465

27-4326290

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)


101 Cambridgepark Drive
Cambridge, MA		02140
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (617) 945-9626

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value $0.001 per share	MCRB	The Nasdaq Stock Market LLC
		(Nasdaq Global Select Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02.

Results of Operations and Financial Condition.

On November 5, 2025, Seres Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2025 and provided operational updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the “Current Report”).

Item 7.01.

Regulation FD Disclosure.

On November 5, 2025, the Company posted an updated corporate presentation in the “Investors and News” portion of its website at www.serestherapeutics.com. A copy of the slide presentation is attached as Exhibit 99.2 to this Current Report and incorporated herein by reference.

The information in Items 2.02 and 7.01 of this Current Report, including Exhibits 99.1 and 99.2 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits

The following Exhibits 99.1 and 99.2 relate to Items 2.02 and 7.01, respectively, and shall be deemed to be furnished, and not filed:


Exhibit No.		Description

99.1		Seres Therapeutics, Inc. Press Release issued November 5, 2025

99.2		Seres Therapeutics, Inc. Corporate Presentation as of November 2025

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Source: View Original Filing on SEC EDGAR